Oxford Global’s Post

The emergence of new modalities like antibody-drug conjugates (ADCs) introduces significant opportunities, challenges, and risks for drug developers. As these technologies evolve, selecting the right moment to increase investments is critical. A recent review by colleagues at BCG provides a deep dive into the ADC landscape, offering perspectives recent innovations across next-gen payloads, carriers, linkers, and conjugation techniques.

The emergence of new modalities like antibody-drug conjugates (ADCs) introduces significant opportunities, challenges, and risks for drug developers. As these technologies evolve, selecting the right moment to increase investments is critical. A recent review by colleagues at BCG provides a deep dive into the ADC landscape, offering perspectives recent innovations across next-gen payloads, carriers, linkers, and conjugation techniques.

Exciting developments are underway in the advanced drug delivery systems market! According to The Business Research Company, this sector is experiencing robust growth and promising future projections. What's driving this expansion? Factors like the rise in chronic conditions due to lifestyle changes are key contributors. These conditions underscore the need for targeted solutions that enhance treatment effectiveness while reducing side effects, ultimately alleviating the burden on healthcare systems. Innovative technologies, including thin film formulations like Shilpa Medicare Limited’s oral paracetamol, are making treatments more palatable and easier to administer, particularly for pediatric patients. Additionally, strategic acquisitions, such as Halozyme Therapeutics acquiring Antares Pharma, are fueling market consolidation and fostering innovation in drug delivery solutions. Market dynamics reveal diverse applications and regional disparities, with North America leading and Asia-Pacific poised for rapid growth. Looking ahead, trends like nanotechnology, smart drug delivery, and AI integration promise an innovative and sustainable future for advanced drug delivery systems. Stay tuned for more insights into this dynamic market! #DrugDelivery #HealthcareInnovation #MarketTrends

The emergence of new modalities like antibody-drug conjugates (ADCs) introduces significant opportunities, challenges, and risks for drug developers. As these technologies evolve, selecting the right moment to increase investments is critical. A recent review by colleagues at BCG provides a deep dive into the ADC landscape, offering perspectives recent innovations across next-gen payloads, carriers, linkers, and conjugation techniques.

Pharmapack Paris January 2024. At Europe's leading Drug Delivery and packaging event 22 January 2024, Paris, over 5,000 attendees representing 363 companies from 70 countries showcased their products and services. 50 different content sessions and panel discussions over the two days enabled insightful and informative discussions with thought-provoking Q&A's. Talks focused on opportunities and challenges in connected drug delivery, next-gen wearable devices, precision drug delivery and ecosystem considerations in adopting large volume on-body injectors all highlighted the significant challenges MedTech and Biopharmaceutical companies face when bringing a new Combination Product & Drug Delivery device to market. Emerging themes spanned personalised drug delivery systems, the rise of digital health technologies including software as medical devices, telemedicine and wearables through to futuristic topics such as digitally connected therapeutics, real-time monitoring and the creation of interactive feedback loops (with the associated regulatory, privacy, ethical and cybersecurity challenges surrounding the careful safeguarding of patient data). With many commentators confirming healthcare is at the very beginning of a twin, bio and digital revolution, the need to accelerate, broaden and deepen collaboration is perhaps greater now than ever before.... Ed Birmingham Soroosh Bagheriasl , PhD Scott Ewan Victoria Ludlow Alaster Stockwell-Jones #collaboration #connection #progress #medtech #innovation #biopharmaceutical  

The emergence of new modalities like antibody-drug conjugates (ADCs) introduces significant opportunities, challenges, and risks for drug developers. As these technologies evolve, selecting the right moment to increase investments is critical. A recent review by colleagues at BCG provides a deep dive into the ADC landscape, offering perspectives recent innovations across next-gen payloads, carriers, linkers, and conjugation techniques.

The emergence of new modalities like antibody-drug conjugates (ADCs) introduces significant opportunities, challenges, and risks for drug developers. As these technologies evolve, selecting the right moment to increase investments is critical. A recent review by colleagues at BCG provides a deep dive into the ADC landscape, offering perspectives recent innovations across next-gen payloads, carriers, linkers, and conjugation techniques.

🔍💼 Partnering with Oxford Global Resources to deliver IoT-powered solutions is a strategic move that promises to revolutionize any business’ approach to healthcare and drug development. Learn more about how we combine industry expertise with technological prowess to create cutting-edge solutions that enhance patient care, streamline manufacturing processes, and improve efficiency in pharmaceutical and life sciences. Read our latest blog post to discover how we fulfill your IoT needs with knowledge, skills, and experience, and our unmatched approach to recruiting and pairing the right talent. With Oxford, you don't have to wait - we've already vetted the right people to provide you with the expertise you need, right now. Spend less time waiting and more time focusing on your company’s future. Our time-honored promise for the last four decades: The Right Talent. Right Now. https://lnkd.in/dCNgTtar #IoT #Healthcare #DrugDevelopment #Pharmaceuticals #LifeSciences #Manufacturing #Biologics #Pharma #MedDevice #TalentAcquisition #OxfordConsulting

What if I told you there was an untapped opportunity for biopharma companies to slash years off their drug development timelines and get life-changing medicines to patients faster? According to new research, optimising one crucial stage of development could reduce timelines by 40-50% (or more). The preclinical stage, from candidate nomination to first-in-human trials, is ripe for improvements that boost speed, simplicity, quality and innovation. By questioning long-held assumptions, embracing new technologies like AI and automation, and taking a cross-functional approach, companies can reach first-in-human trials in as little as 12-15 months. The benefits are huge: faster access to new treatments for patients, longer periods of market exclusivity and patent protection for companies, and hundreds of millions in risk-adjusted net present value per drug. To capture this opportunity, companies need to set speed and innovation as priorities, leverage digital tools, build future-ready operating models, drive continuous process improvements, adopt nimble governance, and develop the right talent. With the right vision and execution, biopharma companies can transform their preclinical development and accelerate the delivery of breakthrough new medicines. Check out the full article here: https://buff.ly/4brqFij #pharma #biotech #manufacturing #data #digital #ai #technology #digitaltransformation #software #IoT #automation #information #knowledgemanagement #drugdevelopment #implementation #IT #OT #PLM #dataintegrity

𝐅𝐨𝐫𝐦𝐮𝐥𝐚𝐭𝐢𝐨𝐧 & 𝐃𝐞𝐥𝐢𝐯𝐞𝐫𝐲 𝟐𝟎𝟐𝟒: 𝐃𝐚𝐲 𝟐, 𝐓𝐫𝐚𝐜𝐤 𝟏 𝐔𝐧𝐯𝐞𝐢𝐥𝐞𝐝 - 𝐒𝐦𝐚𝐥𝐥 𝐌𝐨𝐥𝐞𝐜𝐮𝐥𝐞 𝐃𝐫𝐮𝐠 𝐃𝐞𝐥𝐢𝐯𝐞𝐫𝐲 Embark on a journey through the innovations in Small Molecule Drug Delivery on Day 2, Track 1, featuring a myriad of breakthroughs: 𝐊𝐞𝐲 𝐓𝐨𝐩𝐢𝐜𝐬: - Elevate oral dosage forms for enhanced effectiveness. - Explore advancements in topical & transdermal drug delivery. - Navigate the regulatory landscape and meet expectations. - Strategize with combination products & devices. - Focus on patient-friendly delivery and dosage forms. - Unravel the potential of PROTAC drug delivery for improved bioavailability and clinical applications. - Embrace nanotechnology approaches for superior deliverability and targeted nanoparticle delivery. 𝐖𝐡𝐲 𝐀𝐭𝐭𝐞𝐧𝐝? - Stay ahead with the latest in Small Molecule Drug Delivery. - Learn from industry leaders and experts shaping the field. - Network with professionals driving innovation. 🔗 𝐕𝐢𝐞𝐰 𝐭𝐡𝐞 𝐜𝐨𝐦𝐩𝐫𝐞𝐡𝐞𝐧𝐬𝐢𝐯𝐞 𝐛𝐫𝐨𝐜𝐡𝐮𝐫𝐞 𝐡𝐞𝐫𝐞 👇 https://hubs.la/Q02jtfB_0 🚀 Join us for an enlightening journey into the realm of Small Molecule Drug Delivery! #SmallMoleculeDelivery #DrugDeliveryInnovation #PatientFriendlyForms #OGFormulation #Formulation24